1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Scots fund Novartis' Glivec but not Roche's RoActemra or GSK's Benlysta

 
• By Francesca Bruce

The Scottish Medicines Consortium, Scotland's health technology appraisal body, has agreed to make available on the local NHS Novartis' Glivec (imatinib) for some gastrointestinal stromal tumour (GIST) patients for a longer duration of treatment. However, neither Roche nor GSK were able to convince the consortium to recommend their drugs, RoActemra (tocilizumab, as monotherapy) and Benlysta (belimumab) respectively.

The Scottish Medicines Consortium, Scotland's health technology appraisal body, has agreed to make available on the local NHS Novartis' Glivec (imatinib) for some gastrointestinal stromal tumour (GIST) patients for a longer duration of treatment. However, neither Roche nor GSK were able to convince the consortium to recommend their drugs, RoActemra (tocilizumab, as monotherapy) and Benlysta (belimumab) respectively.

The SMC now says that patients can receive Glivec for the adjuvant treatment of adults at significant risk of relapse...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Dermatological

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

More from Therapeutic Category

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 
• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.